+Follow
parie
No personal profile
23
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
parie
2022-04-30
Buy
Sorry, the original content has been removed
parie
2022-04-30
Sad.
Sorry, the original content has been removed
parie
2022-04-30
Buy!
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586604412538634","uuid":"3586604412538634","gmtCreate":1623511339953,"gmtModify":1650873964316,"name":"parie","pinyin":"parie","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":23,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.24","exceedPercentage":"80.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"80.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9069221591,"gmtCreate":1651295370933,"gmtModify":1676534886815,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069221591","repostId":"1164211724","repostType":4,"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9069223715,"gmtCreate":1651295274950,"gmtModify":1676534886800,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"themes":[],"htmlText":"Sad.","listText":"Sad.","text":"Sad.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069223715","repostId":"2231260527","repostType":4,"isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9069223609,"gmtCreate":1651295245030,"gmtModify":1676534886785,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"themes":[],"htmlText":"Buy!","listText":"Buy!","text":"Buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069223609","repostId":"1117481794","repostType":4,"isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9069223715,"gmtCreate":1651295274950,"gmtModify":1676534886800,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"themes":[],"htmlText":"Sad.","listText":"Sad.","text":"Sad.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069223715","repostId":"2231260527","repostType":4,"isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9069221591,"gmtCreate":1651295370933,"gmtModify":1676534886815,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069221591","repostId":"1164211724","repostType":4,"repost":{"id":"1164211724","kind":"news","pubTimestamp":1651277210,"share":"https://ttm.financial/m/news/1164211724?lang=&edition=fundamental","pubTime":"2022-04-30 08:06","market":"us","language":"en","title":"Is AAPL Stock a Buy After Q1 Earnings? 3 Analysts Weigh In on Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=1164211724","media":"InvestorPlace","summary":"Many investors are closely watching Apple stock after the company warned that it is encountering a n","content":"<html><head></head><body><p>Many investors are closely watching <a href=\"https://laohu8.com/S/AAPL\">Apple</a> stock after the company warned that it is encountering a number of hurdles, including supply chain issues. These problems could lower the tech giant’s revenue during the current quarter by $4 billion to $8 billion, explained CFO Luca Maestri during its Q1 earnings call.</p><p>Despite the news, three Wall Street analysts remained largely upbeat on AAPL stock.</p><p>Calling Apple’s fiscal second-quarter earnings report “very impressive,” Wedbush analyst Dan Ives wrote that the demand for the company’s products remains strong. He expects concerns about Apple’s supply chain issues to diminish later in the year. The analyst kept an “outperform” rating and a $200 price target on Apple.</p><p><b>Analysts Weigh In on AAPL Stock</b></p><p>Also weighing in with an upbeat note today was Morgan Stanley analyst Katy Huberty. Contending that the company’s “ecosystem” is still “remarkably stable,” the analyst nevertheless trimmed her price target on the shares to $195 from $210.</p><p>Meanwhile, Piper Sandler’s Harsh Kumar also remained bullish on Apple’s “ecosystem.” Moreover, he thinks that the firm’s results indicate that it continues to benefit from “strong customer loyalty to both products and services.” Kumar kept a $195 price target and an “overweight” rating on the shares.</p><p>On a more bearish note, Seeking Alpha columnist Bill Maurer stated that the owners of AAPL stock are displeased with Apple’s dividend, which, according to Maurer, is “rather weak.”</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is AAPL Stock a Buy After Q1 Earnings? 3 Analysts Weigh In on Apple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs AAPL Stock a Buy After Q1 Earnings? 3 Analysts Weigh In on Apple\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 08:06 GMT+8 <a href=https://investorplace.com/2022/04/is-aapl-stock-a-buy-after-q1-earnings-3-analysts-weigh-in-on-apple/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Many investors are closely watching Apple stock after the company warned that it is encountering a number of hurdles, including supply chain issues. These problems could lower the tech giant’s revenue...</p>\n\n<a href=\"https://investorplace.com/2022/04/is-aapl-stock-a-buy-after-q1-earnings-3-analysts-weigh-in-on-apple/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2022/04/is-aapl-stock-a-buy-after-q1-earnings-3-analysts-weigh-in-on-apple/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164211724","content_text":"Many investors are closely watching Apple stock after the company warned that it is encountering a number of hurdles, including supply chain issues. These problems could lower the tech giant’s revenue during the current quarter by $4 billion to $8 billion, explained CFO Luca Maestri during its Q1 earnings call.Despite the news, three Wall Street analysts remained largely upbeat on AAPL stock.Calling Apple’s fiscal second-quarter earnings report “very impressive,” Wedbush analyst Dan Ives wrote that the demand for the company’s products remains strong. He expects concerns about Apple’s supply chain issues to diminish later in the year. The analyst kept an “outperform” rating and a $200 price target on Apple.Analysts Weigh In on AAPL StockAlso weighing in with an upbeat note today was Morgan Stanley analyst Katy Huberty. Contending that the company’s “ecosystem” is still “remarkably stable,” the analyst nevertheless trimmed her price target on the shares to $195 from $210.Meanwhile, Piper Sandler’s Harsh Kumar also remained bullish on Apple’s “ecosystem.” Moreover, he thinks that the firm’s results indicate that it continues to benefit from “strong customer loyalty to both products and services.” Kumar kept a $195 price target and an “overweight” rating on the shares.On a more bearish note, Seeking Alpha columnist Bill Maurer stated that the owners of AAPL stock are displeased with Apple’s dividend, which, according to Maurer, is “rather weak.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9069223609,"gmtCreate":1651295245030,"gmtModify":1676534886785,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"themes":[],"htmlText":"Buy!","listText":"Buy!","text":"Buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069223609","repostId":"1117481794","repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week's three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8 <a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc.","BLTE":"Belite Bio, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}